The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
ABBVIE INC. | COM | 00287Y109 | 888 | 10,000 | SH | SOLE | 10,000 | 0 | 0 | ||
ACHILLION PHARMACEUTICALS INC | COM | 00448Q201 | 9,594 | 2,136,800 | SH | SOLE | 2,136,800 | 0 | 0 | ||
ADVAXIS INC | COM NEW | 007624208 | 1,417 | 339,180 | SH | SOLE | 339,180 | 0 | 0 | ||
APRICUS BIOSCIENCES INC | COM NEW | 03832V307 | 2,475 | 1,447,906 | SH | SOLE | 1,447,906 | 0 | 0 | ||
BIOGEN INC | COM | 09062X103 | 120,193 | 383,858 | SH | SOLE | 383,858 | 0 | 0 | ||
BIOVERATIV INC | COM | 09075r100 | 66,486 | 1,165,000 | SH | SOLE | 1,165,000 | 0 | 0 | ||
INNOVIVA INC | COM | 45781M101 | 50,841 | 3,600,705 | SH | SOLE | 3,600,705 | 0 | 0 | ||
MEDICINES CO | COM | 584688105 | 64,894 | 1,752,000 | SH | SOLE | 1,752,000 | 0 | 0 | ||
NOVELION THERAPEUTICS INC | COM NEW | 67001K202 | 7,205 | 1,025,000 | SH | SOLE | 1,025,000 | 0 | 0 |